Insider · CIK 0001854168
Thomas A Fitzgerald
Files at RNAZ (Transcode Therapeutics, Inc.). First filing -, latest -.
In brief
Thomas A Fitzgerald files SEC Form 4 as CFO and director at RNAZ (Transcode Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Thomas A Fitzgerald has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | RNAZ Transcode Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +185,000 | $0.00 | $0 | 185,000 | 32 d ago |
Questions about Thomas A Fitzgerald
Answered from the filings on this page, as of the latest one.
Is Thomas A Fitzgerald buying or selling?
Thomas A Fitzgerald has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Thomas A Fitzgerald's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas A Fitzgerald has 0.
Where does Thomas A Fitzgerald file Form 4?
Thomas A Fitzgerald has filed Form 4 at RNAZ (Transcode Therapeutics, Inc.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.